ALRAMZ

We are asked to act as the RISK lens, a capital-preservation specialist. We need to score concrete breaks based on the cited thresholds: - ocf_to_ni < 0.7 (accrual-heavy earnings) - net_debt_to_ebitda > 4 - ebitda_interest_cover < 2 - liquidity.advv_30d_aed_m < 1 (exit risk) - quarterly_gaps present (unverifiable trend) - dividend cut evident in financial_statements We must check these thresholds and count breaks. Then assign stance: 0 breaks -> BUY, 1 break -> HOLD unless offset, 2+ breaks -> SELL. Never assign SELL without naming which thresholds tripped with figures. Also note: BUY is a legitimate risk-lens output when balance sheet is clean and cash conversion strong. Let's examine the pack. First, ocf_to_ni: from financial_statements.derived.ocf_to_ni = 4.21. This is much greater than 0.7, so no break. Actually ocf_to_ni < 0.7 is the break condition. Here 4.21 > 0.7, so no break. Good. Second, net_debt_to_ebitda: net_debt_to_ebitda = 4.58. This is > 4, so break #1. Need to cite exact figure. Third, ebitda_interest_cover: ebitda_interest_cover = 3.1. This is not < 2, so no break. Fourth, liquidity.advv_30d_aed_m = 0.0967. This is < 1, so break #2. (Exit risk due to low liquidity.) Fifth, quarterly_gaps: "quarterly_gaps": ["no quarter between 2025-06-30 and 2025-12-31"]. This is present (a gap), so break #3. Per the instructions: "quarterly_gaps present (unverifiable trend)" — so any item in quarterly_gaps list means a break. Yes. Sixth, dividend cut evident in financial_statements. We need to check if there's a dividend cut. Look at corporate_actions history and financial statements. corporate_actions shows: 2026 cash dividends 7%, ex-date 2026-05-01. 2024: 0.06% cash dividends? That seems odd (0.06% vs 7% in 2026). But maybe the details are not directly comparable. Also financial_statements.annual.0.dividends_paid for 2025 is 0.0, for 2024 is -33.0 (which might be payment of 33 million, negative indicates outflow? Actually dividends_paid is typically negative cash flow. In the annual data, dividends_paid: 2025: 0.0; 2024: -33.0; 2023: -33.0; 2022: -19.9; 2021: -10.7. So in 2025, they paid 0 dividends, but the corporate action shows a cash dividend in 2026 (ex-date May 2026). The dividend yield is shown as 4.6667% in fundamentals. The payout ratio is 71.8. The question is: is there a dividend cut? According to corporate actions, 2026 dividend is 7% (which likely refers to 7% of par or something). In 2024, there was a 0.06% dividend. That seems like a massive cut from 2022's 4%? Actually 2022: 4%, 2024: 0.06%, 2026: 7%. But we need to interpret from the financial statements. The instruction says "dividend cut evident in financial_statements." The financial statements show dividends_paid: 2025: 0, 2024: -33.0 million. That could be interpreted as a cut from 33 million to 0. But careful: The period for 2025 might have a dividend that hasn't been paid yet? Actually, the ex-date for 2026 cash dividend is 2026-05-01, so the dividend might be for the 2025 fiscal year, declared in 2026. In many accounting, dividends paid in the cash flow statement reflect actual cash outflows during the year. The 2025 cash flow shows 0 dividends paid, meaning they did not pay any dividends in 2025. However, they might have declared a dividend for 2025 that was paid in 2026 (the 7% cash dividend with ex-date 2026-05-01). So the dividend cut would be if the dividend per share is lower. Comparing dividends: In 2024, the corporate action shows "0.06% cash dividends" (that's a very small percentage), while 2026 shows 7%. That seems inconsistent. Possibly "0.06%" is a typo? In the fundamentals, dividend_yield is 4.6667, which is typical. Given the payout ratio of 71.8, that is high but not a cut per se. We need to determine if there's a cut in absolute dividend per share. Without clear prior dividend per share figures, we look at the trend in dividends_paid. 2024: -33.0m, 2023: -33.0m, 2022: -19.9m. In 2025: 0. This might indicate they didn't pay a dividend in 2025 (maybe they suspended it). But then the corporate action shows a 7% dividend in 2026 (ex-date May 2026), which might be a resumption or increase. The filing_context excerpt: "Board proposes dividend of AED 0.06 per share for FY 2023" from 2024, so 0.06 AED per share. For 2022, the dividend was 4% (maybe of par? unclear). Comparatively, 0.06 AED per share vs. prior? In the 2024 corporate action, details: "0.06% cash dividends" seems odd because if it's 0.06 AED per share, and the share price is around 1.5, that's about a 4% yield, consistent with dividend yield of 4.67%. So likely the "0.06%" in the corporate action is a misrepresentation; it's probably 0.06 AED per share. For 2026, the details: "7% cash dividends" — that might be 7% of par value (par is 1 AED? Then 0.07 AED per share). So if prior dividend was 0.06 AED, the 2026 is 0.07 AED, which is an increase, not a cut. But we need to check if there's a cut evident from financial_statements. The financial_statements show dividends_paid: 2025: 0.0, which might just reflect that the 2025 fiscal year dividend was declared in 2026 and hasn't been paid as of the 2025 balance sheet date. Actually, dividends_paid in the cash flow statement for 2025 would include any dividends paid during 2025, which could be the final dividend for 2024. The 2024 dividend might have been paid in 2025. Looking: corporate actions: 2024 ex-date 2024-05-08, so that dividend likely paid in 2024. So the 2025 cash flow showing 0 might mean no dividends were paid in 2025 at all. The 2023 cash flow shows -33.0, which likely includes the 2022 final dividend? Actually, 2022 ex-date 2022-04-28, payment likely in 2022. So 2023 dividends_paid of -33.0 might be for a 2022 special or something? Hard to tell. The payout ratio is 71.8% based on current earnings. So it doesn't appear that there is a clear dividend cut from the financial statements alone. The instructions say "dividend cut evident in financial_statements." I'd say no clear cut is evident; they have dividends but the pattern is not a cut. So I'll deem no break for dividend cut. Thus, breaks: net_debt_to_ebitda > 4 (4.58), advv_30d_aed_m < 1 (0.0967), quarterly_gaps present (gap between Q2 and Q4 2025). That's 3 breaks. So 2+ breaks -> SELL. We must name which thresholds tripped with the cited figures. Also, we need citations. Stance: SELL. Confidence: We need to assign confidence based on the guidelines: 90-100 = multiple independent cited figures align AND a dated catalyst sits inside the horizon. 70-89 = several aligned cited figures, no dated catalyst. 50-69 = clear evidence with real conflicts. 30-49 = mixed or one-sided evidence. 10-29 = thin, stale, or gap-ridden evidence — output HOLD below 40. We have multiple breaks aligning to suggest risk. But is there a dated catalyst inside the horizon? The horizon ends 2026-08-17. The catalysts: recent disclosures: press releases about liquidity provider mandates (June 2026), no major earnings release in the horizon. The most recent results filing was Q1 2026 on 2026-05-11. There's no explicit catalyst dated within the horizon (like an upcoming earnings report). So no dated catalyst. So confidence likely 70-89 range, because several aligned cited figures (net debt/EBITDA > 4, low liquidity, quarterly gaps) but no dated catalyst. We can set confidence at, say, 70 or 75. The evidence is clear, so maybe 70-89. I'll pick 75 as a specific number, but it should be within the range. Let's say 75 is fine. Point: A one-sentence summary citing a figure. For example: "Net debt-to-EBITDA at 4.58x and average daily value traded below AED 0.1 million indicate heightened financial leverage and exit risk." Risk: A one-liner: "High leverage, negligible liquidity, and incomplete quarterly data undermine capital preservation." Target: Derive from pack evidence for the 4-week horizon. Not restate analyst target (none). With a SELL stance, target might be downward. Possibly use the 52-week low or support levels. The low_52w is 1.07. Current price 1.5. With high risk, could target the 200-day MA (1.3463) or lower. But we need to derive from pack. The indicators: pct_below_52w_high is 11.7647, so still not at low. The max drawdown 1y is -18%. So a target might be around support at 1.3? The instructions: "If you output a target, derive it from pack evidence for the 4-week horizon — do not restate analyst.target_mean (a 12-month figure) as your own target." We can set target based on technicals or historical support. The ma200 is 1.3463. ma50 is 1.5208. The current price is 1.5, slightly below ma50. With a SELL, a logical 4-week target could be the 200-day MA or lower. Since liquidity is terrible, the stock might drift lower. I'll set target to the 200-day MA of 1.3463, rounding to 1.35 maybe. Or use the low of 1.07? Too extreme. The 4-week horizon is short, so a moderate drop is plausible. I'll use 1.35 as target. Alternatively, null if uncertain, but let's provide a number. Citations: We need at least 2 for non-HOLD stance. We'll cite the three breaks: net_debt_to_ebitda, advv_30d_aed_m, quarterly_gaps. Order: citations array, point, risk, stance, confidence, target. Now, format JSON. Keys exactly as specified. citations array of objects with field and value. field is dotted path. Example: "financial_statements.derived.net_debt_to_ebitda" with value 4.58. "liquidity.advv_30d_aed_m" with value 0.0967. "financial_statements.quarterly_gaps.0" with value "no quarter between 2025-06-30 and 2025-12-31". Use numbers and strings appropriately. Let's construct: { "citations": [ {"field": "financial_statements.derived.net_debt_to_ebitda", "value": 4.58}, {"field": "liquidity.advv_30d_aed_m", "value": 0.0967}, {"field": "financial_statements.quarterly_gaps.0", "value": "no quarter between 2025-06-30 and 2025-12-31"} ], "point": "Net debt-to-EBITDA of 4.58x and average daily traded value of AED 0.0967M signal elevated leverage and exit risk, while a missing quarterly filing undermines trend verifiability.", "risk": "High leverage, negligible liquidity, and incomplete quarterly disclosures erode capital preservation confidence.", "stance": "SELL", "confidence": 75, "target": 1.35 } Confidence: 75 is within 70-89. I'll use 75. Double-check: The instructions: "Never assign SELL without naming which thresholds tripped, with the cited figures" – we did in point and citations. Also, "BUY is a legitimate risk-lens output when balance sheet is clean and cash conversion strong" – not applicable here as we have breaks. So output is SELL. Target: 1.35, which is just above the MA200 (1.3463). Alternatively, we could use the low of the 52-week range minus some? But 1.35 seems reasonable as a near-term downside target given the negative technicals and poor liquidity. We could also set null, but let's keep a number. The pack has no analyst target to conflict. Thus, final JSON.

We are asked to output JSON with keys: citations, point, risk, stance, confidence, target. The macro-liquidity lens requires cross-sectional analysis: peg and Fed rate are identical for all, so we must cite which of the ALRAMZ's own figures makes it more or less exposed to the macro backdrop compared to the market. We need to cite macro figures (fed_funds_rate, vix, yield_curve_2s10s_pct) for backdrop, and differentiate with name-level figures like fundamentals.debt_to_equity, tv_technicals.beta_1y, liquidity.advv_30d_aed_m, sector, peer_context percentiles. Also weigh uae_macro_news where present. Let's examine the pack: Macro figures: - fed_funds_rate: 3.63 (as of 2026-06-01) - vix: 16.73 (as of 2026-07-16) - yield_curve_2s10s_pct: 0.37 (positive, slightly steepening? Actually 0.37% is positive, not inverted) Company-specific: - fundamentals.debt_to_equity: 1.0307 (103.07%) - tv_technicals.beta_1y: 0.2405 (very low beta, meaning less sensitive to market moves) - liquidity.advv_30d_aed_m: 0.0967 million (~96,700 AED) extremely low, illiquid. - sector: Financial Services - peer_context: pe_percentile 71 (higher than median), div_yield_percentile 59 (slightly above median), median_pe_ttm 11.32, company pe_ttm 15.38, so higher valuation relative to peers. - Also: dividend_yield 4.67%, payout_ratio 71.8, high payout. - Financials: net_debt_to_ebitda: 4.58, ebitda_interest_cover: 3.1 (somewhat leveraged but manageable? debt_to_equity 1.03 is moderate for financials? Actually for a financial services firm, 1.03 is reasonable, but still indicates leverage). - Macro backdrop: Fed funds rate 3.63%, not extremely high but still elevated historically. Yield curve slightly positive, VIX moderate (~16.73) not very high. - ALRAMZ has low beta, so it's less correlated with market swings, which could be a positive in volatile times? But low liquidity might amplify moves if any selling pressure. - The recent news: ALRAMZ launching asset management subsidiary, liquidity provider mandates, etc., positive business developments. - UAE macro news: Mostly positive (Emiratization, payment scheme, BRICS talks), but Houthi naval embargo against Saudi Arabia might create regional geopolitical tension. ALRAMZ is UAE-domiciled, might be affected? But low beta and local focus might insulate it. From macro-liquidity lens: In a moderate rate environment (3.63%), financial services companies with leverage (debt/equity 1.03) could face higher interest expenses. However, ALRAMZ's interest expense was 28.1M in 2025 vs EBITDA 86.5M, coverage 3.1x, so manageable. The yield curve is positive, which is good for financials (borrow short, lend long). But ALRAMZ's business is asset management, brokerage, corporate finance, so not a traditional bank. It might be less rate-sensitive. Low beta suggests it won't amplify market downturns. Very low ADV means liquidity risk: if macro conditions worsen, it might be hard to exit without impact. But for a 4-week horizon, we need short-term view. Confidence: Do we have strong evidence for BUY or SELL? No analyst coverage, no target, no consensus estimate revisions. PE is high relative to peers, but earnings growth is high (EPS growth 154.6% yoy). Revenue growth 43% yoy. ROE 9.4% lower than some peers. Dividend yield 4.67% is decent, above median 4.55 but 59th percentile. Low beta and low liquidity might make it a HOLD, as there's no macro catalyst that disproportionately impacts it. The debt/equity of 1.03 is not extreme. The macro backdrop is not alarming: VIX moderate, curve slightly positive. The UAE macro news is neutral to positive. So, no strong differentiating factor to take a non-HOLD stance. The macro-liquidity lens would likely say HOLD because the name's exposure to macro factors (interest rate sensitivity, market beta, liquidity) is not extreme enough to warrant BUY/SELL relative to the market. But we need to cite at least 2 figures for non-HOLD stance; if HOLD, we can still cite figures. The instruction says: "A non-HOLD stance must cite which of this name's own figures makes it MORE or LESS exposed...". But HOLD is allowed, and below confidence 40 it's HOLD. Here, confidence likely below 40? Let's see: we don't have a catalyst inside the horizon. The last results were Q1 2026 (May 11), next likely Q2 in August 2025? Actually, quarterly season: Q2 usually reported in August? The horizon ends 2026-08-17, so Q2 2026 results might come within the horizon? The catalysts.filings_12mo shows 39 filings, last results filing date 2026-05-11 for Q1. Next likely Q2 results in August? Possibly around Aug 2026. But it's not confirmed. We don't have a specific dated catalyst. So confidence might be in the mixed range (30-49) or lower. Multiple aligned cited figures? We have some figures like low beta, high PE, high dividend, but they point in different directions (high PE negative, high dividend positive, low beta neutral/positive in uncertain times). So mixed evidence. Thus confidence likely 40s? Let's set at 45. Stance: HOLD. Target: Since no strong evidence, target could be null or maybe around current price? The spot is 1.5. With low volatility, maybe target 1.5? But instruction: if you output a target, derive it from pack evidence for the 4-week horizon — do not restate analyst.target_mean. We could set target to null. But better null because we don't have a concrete valuation model. Citations: We need to cite the differentiating figures. For HOLD, we can still cite macro backdrop and name-specific figures that justify the stance. For example: macro.fed_funds_rate 3.63, fundamentals.debt_to_equity 1.0307, tv_technicals.beta_1y 0.2405, liquidity.advv_30d_aed_m 0.0967. But we need at least 2 citations. We'll include a few. Point: Summarize in one sentence citing a figure, e.g., "ALRAMZ exhibits low market sensitivity (beta 0.24) and moderate leverage (D/E 1.03) in a moderate rate environment, suggesting limited macro-driven differentiation over the next 4 weeks." Risk: "Extremely low liquidity (ADV AED 96.7K) amplifies downside if macro sentiment deteriorates, despite low beta." Confidence: 45. Output JSON strictly. Let's make sure field paths are dotted correctly, no brackets. Values as numbers where appropriate. Citations: We'll list several fields: macro.fed_funds_rate, fundamentals.debt_to_equity, tv_technicals.beta_1y, liquidity.advv_30d_aed_m. Maybe also macro.vix and peer_context.pe_percentile. But we need to show that we considered the macro backdrop and the differentiating name-level figure. The key differentiators are beta, leverage, liquidity. So I'll include those. Also, mention the yield curve: macro.yield_curve_2s10s_pct 0.37. But maybe not necessary. I'll construct: { "citations": [ {"field": "macro.fed_funds_rate", "value": 3.63}, {"field": "fundamentals.debt_to_equity", "value": 1.0307}, {"field": "tv_technicals.beta_1y", "value": 0.2405}, {"field": "liquidity.advv_30d_aed_m", "value": 0.0967} ], "point": "ALRAMZ's low beta (0.24) and moderate D/E (1.03) in a 3.63% Fed funds environment imply its macro sensitivity is not markedly above peers, warranting a neutral view.", "risk": "Extremely thin liquidity (ADV AED 96.7K) and high PE (15.4 vs peer median 11.3) could magnify adverse macro shocks.", "stance": "HOLD", "confidence": 45, "target": null } Confidence 45: Mixed evidence, no catalyst. That seems appropriate. Check if any UAE macro news might shift: Houthi naval embargo might increase regional risk, but ALRAMZ is a local financial services firm, likely minimal direct impact. Not enough to change stance. Thus, final answer.

We are asked to output a JSON object for ALRAMZ with keys: citations, point, risk, stance, confidence, target. The stance should be BUY, HOLD, or SELL. Confidence 0-100, target num or null. We are the SECTOR specialist, focusing on business economics, growth, margins, leverage, dividend durability. We need to ground our case in multi-year financial statement trends, not just TTM. Weigh sector_news items. Today is 2026-07-20, horizon ends 2026-08-17 (4 weeks). We must cite exact figures from the pack using dotted paths. Non-HOLD stances need at least 2 citations. No asserting a specific dated catalyst unless it appears in pack. Let's analyze the evidence pack. Company: Al Ramz Corporation Investment and Development P.J.S.C. Sector: Financial Services Spot: 1.5 AED Fundamentals (TTM basis likely): - PE TTM: 15.38 - PB: 1.41 - PS: 4.40 - ROE: 9.43% - ROA: 3.08% - Operating Margin: 43.0% - Net Margin: 27.3% - Revenue Growth YoY: 43.0% - EPS Growth YoY: 154.6% - Debt/Equity: 1.03 - Current Ratio: 1.39 - Dividend Yield: 4.67% - Payout Ratio: 71.8% - Market Cap: 779.7 million AED Financial Statements (annual): 2025: Revenue 153.6M, Gross Profit 80.3M (52.3% margin), Op Income 45.1M (29.4% margin), Net Income 48.3M (31.4% margin), EBITDA 86.5M, Interest Expense 28.1M, OCF 203.3M, Capex -14.8M, FCF 188.5M, Dividends Paid 0, Total Debt 481.5M, Cash 85.1M, Equity 583.1M, Total Assets 1605.2M. 2024: Revenue 114.9M, Gross Profit 64.6M (56.2%), Op Income 22.8M (19.8%), Net Income 16.0M (13.9%), EBITDA 49.8M, Interest Exp 25.7M, OCF -1.0M, Capex -11.9M, FCF -12.9M, Dividends Paid -33.0M, Total Debt 545.0M, Cash 69.2M, Equity 534.9M, Total Assets 1526.1M. 2023: Revenue 104.2M, Gross Profit 47.2M (45.3%), Op Income 36.2M (34.7%), Net Income 39.7M (38.1%), EBITDA 56.5M, Interest Exp 11.2M, OCF -141.5M, Capex -12.3M, FCF -153.8M, Dividends -33.0M, Total Debt 329.6M, Cash 95.5M, Equity 551.9M, Total Assets 1234.3M. 2022: Revenue 114.8M, Gross Profit 60.7M (52.9%), Op Income 25.4M (22.1%), Net Income 32.5M (28.3%), EBITDA 42.4M, Interest Exp 5.3M, OCF -36.7M, Capex -11.4M, FCF -48.0M, Dividends -19.9M, Total Debt 206.5M, Cash 242.3M, Equity 545.2M, Total Assets 986.4M. Trends: - Revenue: 2022 114.8M, 2023 104.2M, 2024 114.9M, 2025 153.6M. Clear high growth in 2025 (43% YoY). Over 2 years (2023 to 2025) rev CAGR = 21.4% (given). - Net Income: 2022 32.5M, 2023 39.7M, 2024 16.0M, 2025 48.3M. Volatile: 2024 dip then 2025 surge. EPS growth YoY 154.6% but from low base. NI CAGR 2y = 10.3%. - Operating Margin: 2022: 22.1%, 2023: 34.7%, 2024: 19.8%, 2025: 29.4%. Fluctuating. - Net Margin: 2022: 28.3%, 2023: 38.1%, 2024: 13.9%, 2025: 31.4%. Also volatile. - OCF: 2022 -36.7M, 2023 -141.5M, 2024 -1.0M, 2025 203.3M. Huge swing to positive. FCF similarly negative except 2025. OCF to NI ratio in 2025 is 4.21, which is very high, possibly due to working capital changes or one-time items. We should be cautious about sustainability. - Debt: increasing: 206.5M (2022) -> 329.6M (2023) -> 545.0M (2024) -> 481.5M (2025). Net Debt: 396.4M (2025 cash 85.1M, debt 481.5M => net debt 396.4M). Net Debt/EBITDA = 4.58. Debt/Equity (latest fundamentals): 1.03, which is moderate but rising from previous years? Actually 2024 D/E was 545/534.9=1.02, 2025 D/E 481.5/583.1=0.83 (lower because debt reduced and equity increased). But fundamentals.debt_to_equity is 1.0307, which might be TTM based on quarter end? Not sure. Anyway, leverage is moderate. Interest coverage: EBITDA/Int Exp = 86.5/28.1 = 3.08 (given). Adequate but not very high. - Dividends: In 2025, dividends paid 0. But corporate_actions shows cash dividends in 2026 (7% cash dividends, ex-date 2026-05-01). Also 2024: 0.06% cash dividends (trivial), 2022: 4%, etc. Dividend yield 4.67%, payout ratio 71.8%. That payout ratio is high relative to net income, but if 2025 net income is 48.3M, 71.8% payout would be about 34.7M dividends. But dividends paid in 2025 statement is 0. Perhaps the payout ratio reflects proposed dividends for 2025 earnings? The 2026 cash dividend of 7% is likely on par value. Paid-up capital is 549.9M, so 7% would be ~38.5M, which matches payout ratio ~71.8% of 48.3M? 48.3*0.718=34.7, close. So dividend durability? In 2025, OCF was strong, so they could afford dividends. However, historically OCF was negative, so the strong OCF may not be sustainable. Need to assess. Sector: Financial Services. Sector news items: Bank of Sharjah Q2 profit up 39%, Oman bank merger, Revolut crypto license, Gulf banks abandoning big bang overhauls. Not directly related to Al Ramz, but generally financial sector in UAE seems positive. Al Ramz is an investment company, not a bank. So sector trends may be somewhat relevant but not directly. Recent disclosures: Liquidity provider mandates, termination of LP agreement, appointment as LP for ADNOC Distribution, etc. Also launch of ARAM Capital. These could be positive for business. Quarterly data: Latest quarter 2026-Q1: revenue 44.0M, net income 12.1M, op income 13.2M, net margin 27.5%, revenue yoy growth 33.7%. Compare to Q1 2025: revenue 32.9M, net income 6.7M. So growth is continuing. TTM revenue likely >153.6M? Q2 2025: 37.5M, Q3 missing (gap), Q4 2025: 38.8M, Q1 2026: 44.0M. Sum of latest four available quarters: Q2 2025 37.5 + Q4 2025 38.8 + Q1 2026 44.0 = 120.3M, plus we need Q3 2025 which is missing. The annual 2025 revenue is 153.6, so Q3 2025 must be 153.6 - (32.9+37.5+38.8) = 44.4M. So TTM (Q3 2025 to Q1 2026): 44.4 + 38.8 + 44.0 = 127.2? Actually TTM would be Q2 2025 to Q1 2026: 37.5+44.4+38.8+44.0 = 164.7M. So TTM revenue is around 164.7M, which implies 7% growth over 2025. Net income TTM: Q2 12.1 + Q3? We need Q3 2025 net income: annual 48.3 - (6.7+12.1+15.9) = 13.6. So TTM NI = 12.1+13.6+15.9+12.1 = 53.7M. So TTM P/E with market cap 779.7M / 53.7 = 14.5, slightly lower than given 15.38 (maybe the fundamentals use a different denominator). Anyway, profitability looks solid. But we must consider the 4-week horizon. There are no specific upcoming catalysts within the horizon (horizon ends Aug 17). The last results filing was May 11 for Q1 2026. Next likely Q2 2026 filing would be around early August? But not given. The horizon ends Aug 17, so Q2 results might be released in early August? Historical: Q1 2026 filed May 11, Q4 2025 filed March 9, Q3 2025 filed Nov 3, Q2 2025 filed Aug 4. So if pattern holds, Q2 2026 results could be around early August, within our horizon. But the pack does not include a scheduled date for next results. The "catalysts.filings_12mo" is 39, indicating many filings, but no dated catalyst. So we cannot assert a specific dated catalyst unless it appears. However, we can note that the next quarterly results might be expected around early August based on history, but we cannot guarantee it. The instructions say: "Do not assert a specific dated catalyst ... unless it appears in a pack field or a filing_context excerpt". Since it does not appear explicitly, we should not rely on it. So we lack a concrete catalyst inside the horizon. That affects confidence. Technical indicators: RSI 48.35, neutral. Price vs MA200: +11.4%. 1-month return -3.2%, 3-month -3.2%, 12-month +28.5%. Relative strength vs DFMGI -10% over 3 months. So underperforming the market recently. DFMGI 1-month -5.96%, 3-month -1.19%. So ALRAMZ has performed worse. Liquidity is very low: ADV 30d AED 0.0967M, which is tiny. Pct below 52w high: 11.76%. So the stock is not very liquid. Consensus signal drift: tv_recommend_all (overall technical rating) 0.0667 (slightly bullish). Technical oscillators and moving averages indicated. But we are sector specialist, so technicals not our main focus. Analyst consensus: none available (n: null, rec: none, target_mean: null). So no analyst estimates. Peer context: median PE 11.32, median PB 1.35, median div yield 4.55. ALRAMZ PE 15.38, PB 1.41, div yield 4.67. So PE is higher than median (71st percentile), PB slightly above median, div yield around median (59th percentile). So valuation is slightly richer than peers on PE, reasonable on PB and yield. Now, as sector specialist, I need to assess business economics, growth, margins, leverage, dividend durability. Growth: Revenue growth YoY 43%, strong. But that's from 2024 to 2025. Multi-year trend: Revenue in 2023 was down from 2022, then up in 2024 and 2025. The CAGR over 2 years is 21.4%, which is decent. Q1 2026 revenue up 33.7% YoY, so growth continuing. However, net income has been volatile: 2023 high due to high margins (net margin 38.1%), 2024 dip due to low margins (13.9%), 2025 recovery (31.4%). This volatility is a concern. The OCF swing from deeply negative to highly positive in 2025 suggests something unusual. It might be due to changes in working capital or investment income. As a financial services firm, revenue and margins can be lumpy, depending on advisory fees, trading income, etc. The business model may not be consistent. Margins: Operating margin: 2022: 22.1%, 2023: 34.7%, 2024: 19.8%, 2025: 29.4%. No clear upward trend, rather cyclical. Net margin similarly. Q1 2026 net margin 27.5%, down from 41% in Q4 2025 but up from 20.4% in Q1 2025. So margins are compressed compared to Q4 2025. This could indicate normalizing. Leverage: Debt/Equity 1.03, moderate. Interest coverage 3.1x, adequate. But net debt to EBITDA 4.58, which is somewhat high. If EBITDA were to decline, debt service could become strained. However, the recent OCF surge could help pay down debt. Dividends were paid in 2026, so they are returning cash to shareholders. Dividend yield 4.67% is decent, but payout ratio 71.8% is high relative to net income. If net income dips again, dividends may be at risk. However, the 2025 OCF was strong enough to cover dividends. But OCF sustainability is questionable. So dividend durability might be moderate. Sector news: The sector_news items don't directly mention Al Ramz or investment firms. They are about banks and fintech. So no direct positive or negative news for our sector lens. Overall, the multi-year trends show high growth in 2025 but with lumpy performance. The valuation is somewhat above peer median on PE, but earnings are volatile, making PE potentially misleading. The stock has underperformed recently, and liquidity is low. For a 4-week horizon, without a clear catalyst and with mixed financial trends, a HOLD stance seems appropriate. Confidence level: if we lack a dated catalyst and have mixed evidence (growth but volatile margins, high valuation relative to peers, low liquidity), confidence might be in the 50-69 range. But we have clear cited figures: revenue growth, net margin trends, debt, etc. Conflicts: strong revenue growth but volatile margins and OCF. No clear catalyst. So I'd put confidence around 60. Stance HOLD. Target null. Now, we must craft citations. At least 2 for non-HOLD stances? But we are HOLD, so maybe no minimum? The rule: "non-HOLD stances need at least 2." So for HOLD, we could have fewer, but we should still cite key figures. We'll cite at least 2. Point: one sentence citing a figure. "ALRAMZ reported 2025 revenue growth of 43% YoY and robust TTM net margin of around 27%, but multi-year margins have been volatile (2024 net margin 13.9%) and operating cash flow swung from -141M in 2023 to +203M in 2025, raising sustainability concerns." Risk: one line. "Low liquidity and a lack of imminent catalysts may inhibit price movement within the 4-week horizon." Now, citations: we need dotted paths and values. For example: - {"field":"financial_statements.annual.0.revenue","value":153.6} and maybe another year to show growth. - {"field":"financial_statements.annual.0.net_margin_pct","value":31.4} and {"field":"financial_statements.annual.1.net_margin_pct","value":13.9} to show volatility. - {"field":"financial_statements.annual.0.ocf","value":203.3} and {"field":"financial_statements.annual.2.ocf","value":-141.5} - Also potentially {"field":"fundamentals.rev_growth_yoy","

We are asked to produce a JSON with a TECHNICAL lens, focusing on trend (MA50 vs MA200, price vs MA200), momentum, vol, drawdown/gap structure, relative strength vs DFMGI. Also consider corporate_actions.ex_date as mechanical, not a signal. The horizon is 4 weeks ending 2026-08-17. We need to reason over the pack and cite exact figures. The output should be a single JSON with keys: citations, point, risk, stance, confidence, target. First, identify key technical indicators from the pack. Fields: indicators.ma50=1.5208, indicators.ma200=1.3463, indicators.pct_vs_ma200=11.4176 (so price is above MA200 by 11.4%), indicators.ret_1m_pct=-3.2258, ret_3m_pct=-3.1987, ret_12m_pct=28.5395. RSI14=48.3537 (near neutral, slightly below 50). realized_vol_annual_pct=18.4395. rel_strength_3m_vs_dfmgi_pct=-10.0506 (underperforming index). max_drawdown_1y_pct=-18.0328. pct_off_20d_high=0.0 (meaning price is at the 20-day high? Actually 0.0 means it's at the 20-day high, maybe the latest price is the high of the last 20 days). atr14_pct_of_price=0.1905 (very low volatility). largest_gap_3m_pct=5.2288. pct_no_trade_days_3m=4.6875. tv_technicals: adx=29.0403 (trend strength moderate, below 25 is weak, above 25 is trend, 29 is decent), cci20=51.2821 (slightly bullish), stoch_k=100.0 (overbought), williams_r=0.0 (overbought). beta_1y=0.2405 (very low beta, low correlation with market). tv_recommend_all=0.0667 (slightly bullish), tv_recommend_ma=0.1333, tv_recommend_other=0.0. consensus_signal_drift: tv_recommend_all=0.1167, delta_5d=0.05, delta_10d=0.117 (positive drift). Also corporate_actions: history.0.ex_date=2026-05-01 (cash dividend 7%). That ex-date is past (May 1), so the drop has already happened. Since it's past, it doesn't affect our horizon directly. But we note it as mechanical. Now, interpret for technical stance. Price is above both MA50 and MA200? MA50=1.5208, MA200=1.3463, spot=1.5. Spot is slightly below MA50 (1.5 < 1.5208) so price is below the 50-day MA. That's a short-term bearish sign. But it's above the 200-day MA by 11.4%, so long-term uptrend intact. The price is at the 20-day high (pct_off_20d_high=0.0), meaning it has recovered to the highest point of the last 20 days. However, it has negative 1-month and 3-month returns. RSI is neutral, not overbought or oversold. Stochastic and Williams %R are overbought, suggesting potential short-term pullback. ADX at 29 indicates a trend, but not extremely strong. Relative strength vs DFMGI is -10%, underperforming the market. DFMGI ret_1m is -5.958%, ret_3m -1.1938%, so ALRAMZ underperformed even more. The low volatility (ATR 0.19%) and low beta (0.24) indicate the stock is not very volatile. The low liquidity (advv_30d_aed_m=0.0967 million) could be a concern. Overall, technical picture is mixed: long-term trend up, short-term consolidation with slight bearish bias. No strong momentum either way. The recent 1-month drop of -3.2% while the market dropped -6%, so relative strength might be improving? But rel_strength_3m is -10%, so still lagging. Given the technical lens only, we need to decide stance for 4-week horizon. Since price is below MA50, RSI neutral, overbought stochastic, and low volume, it might be prone to consolidation or slight downside. But it's also at 20-day high, which could break out. The confidence might be low because evidence is mixed. The dividend ex-date is past, no upcoming corporate actions to cause mechanical drop. The filing_context and news mention liquidity provider mandates and new subsidiary, but those are fundamental, not technical. As a technical lens, we ignore those. The technicals alone suggest a cautious stance. Could be HOLD. Confidence bands: 50-69 = clear evidence with real conflicts. There are conflicting signals: price above MA200 but below MA50; RSI neutral; overbought stochastic; low volatility. So confidence maybe around 55-60. But we need to output HOLD if confidence below 40. Here confidence >40 so could be BUY or SELL, but given mixed, likely HOLD. Actually the instructions say: "output HOLD below 40" but that doesn't mean we must output HOLD if confidence is above 40; it means if confidence <40, stance must be HOLD. So we can output BUY/SELL/HOLD as determined. Given technicals, I'd lean HOLD because no clear trend for next 4 weeks. But the question is: should we output BUY because of long-term uptrend? The horizon is only 4 weeks, so short-term signals matter. Short-term signals are bearish (below MA50, negative 1m return). So HOLD is appropriate. Point: one sentence citing a figure, e.g., "Price at 1.5 is 1.4% below the 50-day MA of 1.5208, while 11.4% above the 200-day MA, with RSI neutral at 48.4, indicating consolidation." Risk: something like "Low liquidity and overbought stochastic may cause choppy price action." Target: For 4-week horizon, derive from pack evidence. The pack does not provide a target directly. We might derive from technical patterns? But we have no explicit target. The instructions say: "If you output a target, derive it from pack evidence for the 4-week horizon — do not restate analyst.target_mean (a 12-month figure) as your own target." Since there's no analyst target (analyst.target_mean=null), and no clear technical level from the pack (like a resistance from moving averages), we might set target to null. Or we could use MA50 as a resistance target? But it's not a strong signal. Given the horizon, maybe no target. I'll set target to null. Citations: need at least 2 non-HOLD stances. For HOLD, maybe one or two citations are fine. I'll cite indicators.ma50, indicators.pct_vs_ma200, indicators.rsi14, etc. Let's pick: {"field":"indicators.ma50","value":1.5208}, {"field":"indicators.pct_vs_ma200","value":11.4176}, maybe also rel_strength. So I'll use: {"field":"indicators.ma50","value":1.5208}, {"field":"indicators.pct_vs_ma200","value":11.4176}, {"field":"indicators.rsi14","value":48.3537} Output order: citations, point, risk, stance, confidence, target. Confidence: I'll assign 55. Mixed evidence, no dated catalyst, but some technical conflict. Thus JSON: { "citations": [ {"field": "indicators.ma50", "value": 1.5208}, {"field": "indicators.pct_vs_ma200", "value": 11.4176}, {"field": "indicators.rsi14", "value": 48.3537} ], "point": "Price at 1.5 is 1.4% below the 50-day MA of 1.52 and 11.4% above the 200-day MA, with RSI neutral at 48.4, signaling consolidation.", "risk": "Low liquidity and overbought stochastic may cause choppy price action.", "stance": "HOLD", "confidence": 55, "target": null }

We are the Valuation lens. We need to output a JSON with stance, confidence, target, point, risk, and citations. We must consider multiples vs fair value, dividend support, analyst consensus (though there is no analyst coverage here), and drift. The pack shows no analyst coverage: analyst.n is null, rec is "none", target_mean null, etc. So we rely on fundamentals, dividend, and consensus_signal_drift. First, note the horizon: 4 weeks ending 2026-08-17. Today is 2026-07-20. Latest price: 1.5. We need to assess valuation. Key multiples: PE TTM 15.38, PB 1.41, PS 4.40. Peer context: median PE 11.32, median PB 1.35, median div yield 4.55. So ALRAMZ trades at a premium to peers on PE (71st percentile) and slightly premium on PB. Dividend yield: 4.67% vs median 4.55%, so around median. Payout ratio 71.8% - high but covered? Look at cash flows: OCF 203.3M, FCF 188.5M in 2025. Dividends paid 0.0 in 2025? Wait, dividends_paid in 2025 is 0.0, but corporate actions show a 7% cash dividend in 2026 with ex-date 2026-05-01, payment date 2026-05-18. The 2025 financial statements show dividends_paid 0.0, meaning no dividend was paid in 2025? That might be because the dividend for fiscal 2025 was declared later (after year-end). The 7% dividend was in 2026. So dividend support: the company paid dividends in the past, but the current year's dividend just got paid. The yield 4.67% is based on the latest dividend (probably the 7% cash dividend). Derived FCF margin 122.7% - that's weird, but FCF in 2025 was huge due to OCF of 203.3M and capex only 14.8M. So FCF covers dividend easily. However, past dividends have been inconsistent: 2024 had 0.06% dividend (negligible), 2022 4%, etc. The current dividend is 7% which at 1.5 share price implies 0.105 AED per share? Not sure. The dividend yield is 4.67%, so that's decent. But the payout ratio of 71.8% might be based on net income. In 2025, net income 48.3M, dividend paid? Actually, the dividend paid in 2025 was 0.0, so the payout ratio might be based on declared dividends? fundamentals.payout_ratio is 71.8. That could be based on the latest declared dividend relative to earnings. So dividends are supported by earnings and cash flows. Now, operations: revenue grew 43% yoy in 2025, net income surged 154% yoy. Strong growth. But the PE of 15.4 is high relative to peers' 11.3. However, growth might justify it. But for a valuation lens, we look at whether the stock is overvalued/undervalued. Given peer median PE 11.32, ALRAMZ's PE is 36% higher. PB is 1.41 vs 1.35, slight premium. Dividend yield slightly above median. So on a relative basis, it seems overvalued. Technical indicators: RSI 48.35, neutral. Price vs MA200 up 11.4%, but 3-month return -3.2%, underperforming DFMGI by -10%. Consensus signal drift: tv_recommend_all 0.1167, positive drift (delta 10d 0.117). That suggests improving analyst sentiment, but since there are no traditional analysts, this is from TradingView technicals? Probably based on moving averages, oscillators. tv_technicals.recommend_all is 0.0667 (neutral). So slight positive. Dividend: corporate actions show a recent 7% dividend paid in May 2026. The stock went ex-div on May 1. So the dividend is already captured. No further dividend expected in the 4-week horizon (next ex-date likely next year). So dividend support is not a catalyst. Recent news: liquidity provider mandates, asset management subsidiary launch. Not specific dated catalysts within horizon. Results: last results filing Q1 2026 on May 11. Next results likely for Q2 2026? Usually within 45-60 days after quarter end. Quarter ended June 30, so Q2 results might come in August? Possibly within our horizon (ending Aug 17). That could be a catalyst: Q2 2026 results. But we don't know if it's confirmed. The catalysts.results_filing_dates_24mo show a pattern: Q2 results for 2025 were on Aug 4? Actually, list: "2025-08-04" - that's probably Q2 2025 results. So historically, they report Q2 in early August. So there is a reasonable expectation of Q2 2026 results during our horizon. That is a dated catalyst. But we must not assert it as a fact unless it's in the pack. The pack only shows last_results_filing date 2026-05-11 (Q1) and the upcoming ones are not mentioned. The excerpt from filing_context shows a preliminary result for 2025 dated Feb 14, 2026. No mention of Q2 release. So we cannot claim a specific dated catalyst. Therefore, no strong catalyst within horizon. Given the premium valuation relative to peers but strong growth and solid dividend, the stock might be fairly valued to slightly overvalued. But we need to decide stance. Our lens: Valuation. Typically, if overvalued, we might say SELL, if undervalued, BUY. But with PE 15.4 vs peer median 11.3 and PB marginally higher, it's overvalued. The high growth might justify a higher multiple, but the net margin is high (27.34%), so earnings quality looks good. However, the 2-year CAGR of net income is only 10.3% despite last year's surge (was down in 2024). So growth is lumpy. The forward outlook? Q1 2026 net income 12.1M, annualizing gives ~48.4M, similar to 2025. So no acceleration. So PE might not compress. On dividend, the yield is around peer median, so no special attraction. The consensus drift positive might indicate improving sentiment, but from a valuation standpoint, it's not cheap. Confidence: we have conflicts: high growth vs high multiple. No dated catalyst (although Q2 results might be soon, not confirmed). So confidence maybe 50-69. Stance: Since overvalued relative to peers, possibly HOLD or SELL? The instruction says output HOLD below 40 confidence, but we can choose SELL if confidence is sufficient. But given the strong growth and positive technical drift, a SELL might be premature within 4 weeks. Typically, valuation-based SELL would need a catalyst or clear overvaluation. Without a catalyst, a HOLD is safer. But we are to weigh fundamentals and consensus drift. Consensus drift positive suggests upgrades, but from TradingView, not analyst. The tv_recommend_all had a strong positive delta. That might indicate improving price momentum. But price has pulled back -3% in 1 month. So maybe overvaluation is being corrected? We could argue HOLD with a slight negative bias. However, we need a stance. Let's see if we can derive a target. For a SELL, we might set a target lower, like towards peer median PE. Peer median PE 11.32 * TTM EPS. TTM EPS =? We have Q1 2026 net income 12.1M, plus last three quarters from 2025: Q4 2025 15.9M, Q3 2025? Missing; we have Q2 2025 12.1M, Q1 2025 6.7M. Actually, quarterly data: Q1 2026 12.1, Q4 2025 15.9, Q3 2025? There's a gap: we have Q2 2025 (period 2025-06-30) net income 12.1, and then Q4 2025 (2025-12-31) 15.9, so Q3 2025 is missing. So TTM calculation: we need last 4 quarters: Q1 2026 + Q4 2025 + Q3 2025 + Q2 2025. Q3 2025 missing, but we can infer from annual: 2025 annual net income 48.3. Sum of known quarterly: Q1 2025=6.7, Q2 2025=12.1, Q3=? , Q4 2025=15.9. So Q3 = 48.3 - (6.7+12.1+15.9) = 13.6. So TTM net income = Q1 2026 12.1 + Q4 2025 15.9 + Q3 2025 13.6 + Q2 2025 12.1 = 53.7M. But wait, that uses Q2 2025 which is old. Better to use last 4 available: Q1 2026, Q4 2025, Q3 2025, Q2 2025. So TTM = 12.1+15.9+13.6+12.1=53.7M. Market cap is 779.7M, so PE TTM = 779.7/53.7 = 14.52, close to given 15.38 (maybe they used different earnings). Anyway, using peer median PE 11.32, fair value would be 11.32 * 53.7 = 607.9M market cap, divided by shares? Shares outstanding: market cap / price = 779.7/1.5 = 519.8M shares? Actually, market cap 779.7M, price 1.5, so shares roughly 519.8M. That seems high for a UAE company. Anyway, target price per share = 607.9/519.8 = 1.17. That's a -22% downside. But that's a crude valuation. PB: equity 583.1M, shares 519.8M gives book per share ~1.12, so at 1.5, PB 1.34. Peer median PB 1.35, so fairly valued on PB. So on PB, it's fairly valued. So no strong overvaluation signal from PB. So maybe it's fairly valued. Dividend yield slightly above median. So overall, the stock appears fairly valued to slightly overvalued on PE, but fairly valued on PB and dividend. Growth is strong but may be priced in. Without a catalyst, a HOLD seems appropriate. Confidence: Mixed evidence, no clear catalyst. Confidence 50-69. We'll go with 60. Stance: HOLD. Target: null, as HOLD often doesn't have a specific target, or we can set target near current price? The instruction says: "If you output a target, derive it from pack evidence for the 4-week horizon". For a HOLD, we might not output a target, but we can if we want. Since the stock is fairly valued, we could set target as current price or slightly lower. But better to set null. Point: "ALRAMZ trades at a PE of 15.4x, a 36% premium to the peer median of 11.3x, but PB of 1.41 is in line with peer median 1.35 and dividend yield of 4.67% is slightly above median 4.55%, suggesting fair value." Actually, I need to cite exact figures. Risk: "Downside risk from premium PE multiple compression if growth stalls or market sentiment shifts, though strong FCF and dividend provide support." Now citations: we must cite at least 2 fields for non-HOLD stance? Actually, the instruction says non-HOLD stances need at least 2 citations. Since we might output HOLD, we don't strictly need 2? But better to include anyway. We'll cite fundamentals.pe_ttm, peer_context.median_pe_ttm, fundamentals.dividend_yield, etc. We need to output JSON with keys in order: citations, point, risk, stance, confidence, target. Let's build the citations list. We'll use: - {"field":"fundamentals.pe_ttm","value":15.3846} - {"field":"peer_context.median_pe_ttm","value":11.32} - {"field":"fundamentals.pb","value":1.4145} - {"field":"peer_context.median_pb","value":1.35} - {"field":"fundamentals.dividend_yield","value":4.6667} - {"field":"peer_context.median_div_yield","value":4.55} Confidence: 60. Point: "ALRAMZ's PE of 15.4x is a 36% premium to peer median 11.3x, but PB of 1.41 is near peer median 1.35 and dividend yield of 4.67% slightly exceeds peer median 4.55%, indicating fair value overall." Risk: "Multiple compression risk if growth disappoints, though robust FCF (122.7% margin) and dividend support mitigate downside." Note: use exact figures from pack. Let's ensure we're not inventing anything. All values from pack. Target: null. Stance: HOLD. Output JSON.